Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascentage Granted US Orphan Drug Status for Gastric Cancer Treatment

publication date: Sep 14, 2020

Ascentage Pharma of Suzhou was granted Orphan Drug Designation in the US for a novel MDM2-p53 inhibitor as a treatment for gastric cancer. It is the first ODD for APG-115. Although GC is a rare disease in the US, it is the third leading cause of cancer deaths worldwide, with a very high incidence in China and Japan. Ascentage said APG-115 has shown promising results in preclinical GC tests. One week ago, Ascentage reported its novel Bcl-2 inhibitor was awarded ODD in the US for chronic lymphocytic leukemia. More details....

Stock Symbols: (HK: 6855)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.